TAMI-33. AURKA INHIBITION REPROGRAMS METABOLISM AND IS SYNTHETICALLY LETHAL WITH FATTY ACID OXIDATION INHIBITION IN GLIOBLASTOMA

Aurora kinase A (AURKA) has emerged as a viable drug target for glioblastoma (GBM), the most common malignant primary brain tumor in adults with a life expectancy of 12-15 months. However, resistance to therapy remains a critical issue, which partially may be driven by reprogramming of metabolism. B...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Nguyen, Trang, Shang, Enyuan, Shu, Chang, Mela, Angeliki, Humala, Nelson, Mahajan, Aayushi, Quinzii, Catarina, Westhoff, Mike-Andrew, Karpel-Massler, Georg, Bruce, Jeffrey, Canoll, Peter, Siegelin, Markus
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
Tumor Microenvironment/Angiogenesis/Metabolism/Invasion
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651513/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.921
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars